 ESSA Pharma Inc. ESSA, or the Company NASDAQ: EPIX, TSX-V: EPI, a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal year ended September 30, 2019. All references to in this release refer to United States dollars, unless otherwise indicated. 